SFX by Ex Libris Inc.

Title:	Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options
Source:	Blood [0006-4971] Stumpel, Dominique J. P. M. yr:2009

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Imamura, T. "Frequent co‐expression of HoxA9 and Meis1 genes in infant acute lymphoblastic leukaemia with MLL rearrangement." British journal of haematology 119.1 (2002): 119-.
description	2.	Cleary, Michael L. "Regulating the leukaemia stem cell." Best Practice & Research Clinical Haematology 22.4 (2009): 483-487.
description	3.	Krivtsov, Andrei V. "Transformation from committed progenitor to leukemia stem cells." Annals of the New York Academy of Sciences 1176 (2009): 144-149.
description	4.	Sara Marino, Federico Verzegnassi, Paolo Tamaro, Gabriele Stocco, Fiora Bartoli, Giuliana Decorti, Marco Rabusin;, S. "Response to glucocorticoids and toxicity in childhood acute lymphoblastic leukemia: Role of polymorphisms of genes involved in glucocorticoid response." Pediatric blood & cancer 53.6 (2009): 984-991.
description	5.	Ellis, M. "Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial." Journal of clinical oncology 19.18 (2001): 3808-3816.
description	6.	Rowley, Janet D. "Chromosomes in leukemia and beyond: from irrelevant to central players." Annual review of genomics and human genetics 10.1 (2009): 1-18.
description	7.	Wang, Y. "The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML." Science 327.5973 (2010): 1650-1653.
description	8.	Min, M. "High dose methotrexate population pharmacokinetics and Bayesian estimation in patients with lymphoid malignancy." Biopharmaceutics & drug disposition 30.8 (2009): 437-47.
description	9.	Kersey, Ashish J. "A role for MEIS1 in MLL-fusion gene leukemia." Blood 113.8 (2008): 1756-1758.
description	10.	Xiao, S. "Overexpression of the novel oncogene SALL4 and activation of the Wnt/β-catenin pathway in myelodysplastic syndromes." Cancer genetics and cytogenetics 194.2 (2009): 119-24.
description	11.	Sawada, Sakata N. "Significance of four MRD markers in MRD-based treatment strategy for childhood acute lymphoblastic leukemia." Leukemia Research 33.12 (2009): 1710-1713.
description	12.	Chowdhury, T. "Insights from clinical studies into the role of the MLL gene in infant and childhood leukemia." Blood cells, molecules & diseases 40.2 (2008): 192-9.
description	13.	Jamieson, C. "The MLLgnant consequences of reverting to an embryonic transcriptional program." Cell stem cell 4.2 (2009): 97-8.
description	14.	Brousse, V. "Does regular blood transfusion prevent progression of cerebrovascular lesions in children with sickle cell disease?" Annals of hematology 88.8 (2009): 785-8.
description	15.	Litzow, M. "The therapy of relapsed acute leukaemia in adults." Blood Reviews 18.1 (2004): 39-63.
description	16.	Chen, C L L. "Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukemia." Blood 89.5: 1701-7.
description	17.	Miura, Y. "Cytokine and chemokine profiles in autologous graft-versus-host disease (GVHD): interleukin 10 and interferon gamma may be critical mediators for the development of autologous GVHD." Blood 100.7 (2002): 2650-8.
description	18.	Carey, Lisa A., Lisa A A. "Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study." JAMA 295.21 (2006): 2492-2502.
description	19.	Milne, Thomas A A. "MLL Targets SET Domain Methyltransferase Activity to Hox Gene Promoters." Molecular cell 10.5 (2002): 1107-1117.
description	20.	Kuerer, H M M. "Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy." Journal of clinical oncology 17.2 (1999): 460-9.